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Abstract
1,25(OH)2D is the hormonally active form of vitamin D known for its  
pleiotropic immunomodulatory effects. Via altering gene transcription, 1,25(OH)
D exerts immunosuppressive effects and stimulates immune regulation. Recently, 
the interest in vitamin D in association with autism spectrum disorder (ASD) has 
been triggered. The prevalence of ASD has increased excessively over the last few 
decades, emphasizing the need for a better understanding of the etiology of the 
disorder as well as to find better treatments. Vitamin D levels in ASD patients are 
observed to be lower compared to healthy individuals and maternal vitamin D 
deficiency has been associated with an increased risk of ASD. Moreover, vitamin D 
supplementation improves ASD symptoms. These recent clinical findings strongly 
suggest that vitamin D is a factor in ASD onset and progression. Yet, possible 
mechanisms behind this association remain unknown. This review summarizes 
immunomodulatory properties of vitamin D and peripheral immune dysregulation 
in ASD, after which possible mechanisms via which vitamin D could rebalance the 
immune system in ASD are discussed. Although promising clinical results have 
been found, further research is necessary to draw conclusions about the effect and 
mechanisms behind the effect of vitamin D on ASD development.
Keywords: autism spectrum disorder, vitamin D, vitamin D receptor,  
vitamin D responsive element, immune system
1. Introduction
For many decades vitamin D has been known for its immunomodulatory effects. 
When metabolized into the active hormone calcitriol, it can bind to vitamin D 
receptors (VDRs). These VDRs are expressed by most cells in the human body, 
allowing vitamin D to have a broad range of functions. Upon binding of vitamin 
D to a VDR, gene transcription is altered. All types of immune cells in the human 
body express the vitamin D receptor, enabling vitamin D to alter immune responses 
[1]. In general, vitamin D has immunosuppressive properties and can therefore 
be beneficial in diseases characterized by inflammation and autoimmunity such 
as multiple sclerosis and inflammatory bowel disease [2]. Vitamin D deficiency is 
an increasing global problem with an estimated 30% of the population suffering 
from vitamin D deficiency and 60% being vitamin D insufficient [3]. Inadequate 
levels of vitamin D can have many adverse effects throughout the body due to the 
abundant expression of VDRs. Furthermore, maternal vitamin D deficiency has 
been suggested to affect development of the offspring. To date, the World Health 
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Organization does not recommend vitamin D supplementation to pregnant women. 
This illustrates the lack of awareness on the importance of vitamin D in health.
A disorder that recently received increased attention is autism spectrum dis-
order (ASD). ASD is a heterogeneous neurodevelopmental disorder, collectively 
describing autistic disorder, Asperger’s syndrome and Pervasive Developmental 
Disorders Not Otherwise Specified (PDD-NOS). It is characterized by behavioral 
deficits, impaired communicative functioning and restricted and repetitive patterns 
of behavior [4]. ASD onset usually occurs in the first few years of life and proceeds 
into childhood and adulthood [5]. Genetics are of importance in the disorder – 
several studies show monozygotic twins share 60–90% of ASD symptoms [5, 6]. 
Additionally, ASD is four times more prevalent in boys, which is suggested to be due 
to the protective effects of estrogens in women [5, 7].
Despite the role of genetics, the prevalence of ASD has increased tremendously 
over the past few decades [8]. In the Netherlands, the prevalence of ASD increased 
from 90.000 to 190.000 cases between 2001 and 2009 [9]. More recently, the 
prevalence of ASD in the US was estimated at one in every 59 children aged eight 
years in 2014, which increased to one in every 54 children in 2016 [10]. Across all 
ages, the prevalence of ASD is estimated to be 1% of the worldwide population 
[11, 12]. Partially, this increase can be explained by improved diagnostics and 
increased awareness. However, the sudden and rapid increase also suggests the role 
of environmental factors in ASD onset. Research indicates that genetic predisposi-
tion predominates, requiring additional environmental triggers to develop ASD. 
Multiple environmental factors have been suggested, including antibiotic use, 
maternal infections during pregnancy and sun exposure. The strong increase in 
prevalence highlights the importance of understanding the role of environmental 
factors in the etiology of ASD [6].
The association between vitamin D and ASD was suggested in 2008 when it was 
observed that the increase in ASD prevalence coincides with the medical advice 
to avoid sun exposure [7]. Since then, clinical trials have been performed, trying 
to prove the association between vitamin D and ASD. UV-B is the most important 
source of vitamin D in humans, illustrating the requirement for sunlight. Research 
shows ASD prevalence is higher in countries at higher latitudes, coinciding with 
reduced UV-B intensity. Moreover, ASD patients consistently exhibit lower vitamin 
D levels than healthy individuals and studies have shown maternal vitamin D 
deficiency increases the risk of ASD. These findings encouraged scientists to study 
the effect of vitamin D supplementation on improving ASD symptoms, and thus far 
promising results have been found [7, 13]. Yet, the mechanisms behind the possible 
association between vitamin D and ASD remain unknown. Neuroinflammation, 
oxidative stress, autoimmunity and immune dysregulation are all observed in 
individuals with ASD [14]. Of these phenomena, immune dysregulation is the least 
well-described in literature. ASD patients suffer from chronic systemic inflamma-
tion, which is illustrated by a disbalance in cytokine expression and the presence of 
comorbidities such as gastrointestinal problems in a large fraction of ASD patients 
[15]. Increased immune activation is observed in ASD patients and is associated 
with more severe symptoms [16]. Taking into consideration the immunosuppressive 
properties of vitamin D, this suggests that perhaps vitamin D could play a role in 
rebalancing the dysregulated immune system in ASD patients and thereby reduce 
systemic inflammation. However, to date there is no recommendation for vitamin D 
supplementation in ASD patients.
Therefore, in this review the role of vitamin D in immune dysregulation in 
ASD patients is examined. First, immunomodulatory properties of vitamin D in 
general and peripheral immune dysregulation in ASD are described, with a focus on 
CD4+ T cell activity. Next, possible mechanisms behind this effect of vitamin D on 
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immune dysregulation in ASD are discussed. This review is summarizing current 
knowledge on vitamin D and ASD and to examine possible mechanisms via which 
vitamin D might slow ASD development.
2. The immunomodulatory properties of vitamin D
2.1 Vitamin D: production and metabolism
Vitamin D is a steroid hormone with varying functions in the human body. 
Vitamin D precursors are extracted both from food and through the exposure to 
sunlight. Around 10% of the total amount of vitamin D in the body is provided by 
dietary sources and supplements [17]. There are two forms of vitamin D precur-
sors: D2 (ergocalciferol) and D3 (cholecalciferol). Some plant products are rich in 
vitamin D2, whereas vitamin D3 is present in animal products, including fish and 
egg yolk [18]. Sunlight exposure accounts for about 90% of vitamin D and is thus 
the most important source of this vitamin [17]. When the human skin is exposed 
to UV-B, 7-dehydrocholesterol is converted into pre-vitamin D [19]. This process 
depends on factors such as UV-B intensity, skin color and coverage of the skin.
After the production of vitamin D3 in the body, it is first metabolized into the 
precursor 25-hydroxyvitamin D (25(OH)D). This reaction is performed in the 
liver by hydroxylases, of which CYP2R1 has the highest affinity for pre-vitamin 
D [20]. Vitamin D binding protein functions as a transporter of 25(OH)D to the 
kidney. Consequently, 1,25-dihydroxyvitamin D (1,25(OH)2D) is formed in the 
kidney by the enzyme CYP27B1. The activity of this enzyme is essential to produce 
bioactive vitamin D. 1,25(OH)2D is the hormonally active form of vitamin D [21]. 
In this review 1,25 (OH)2D reflects bioactive vitamin D. Besides renal CYP27B1, 
other cells in the human body can also express this enzyme. In this way, vitamin D 
can be directly synthesized not solely in the kidney but also in other tissues [20]. 
1,25(OH)2D can be absorbed and then bind to the intracellular vitamin D receptor 
(VDR). Due to the lack of 1,25(OH)2D in its free form in the blood, vitamin D levels 
are based on 25(OH)D. This precursor is bound to vitamin D binding protein (DBP) 
in the circulation, allowing measurements to determine vitamin D levels [22, 23].
1,25(OH)2D can influence its own serum levels and binding to VDR. When 
serum 1,25(OH)2D levels are high, this enhances VDR expression. Moreover, 
1,25(OH)2D has a negative feedback on CYP27B1, the enzyme involved in 
1,25(OH)2D synthesis. Besides self-regulation, parathyroid hormone (PTH) 
and fibroblast growth factor 23 (FGF23) are important regulators of vitamin D 
metabolism. To sustain normal systemic vitamin D levels, CYP24A1 is stimulated by 
1,25(OH)2D and degrades vitamin D. The CYP24A1 enzyme is present in all vitamin 
D target cells, resulting in the ability to regulate intracellular vitamin D levels [20].
2.2 Vitamin D: mode of action
By binding to VDR, which has a DNA-binding domain, 1,25(OH)2D can exert 
effects on the body through gene transcription. VDRs are located intracellularly 
in a wide range of cells. Due to this, vitamin D can exert effects on many different 
biological processes in the body [21, 24]. The regulation of genes by VDR is cell 
specific. After the binding of vitamin D to VDR, VDR interacts with the retinoic X 
receptor (RXR). The VDR/RXR heterodimer binds to vitamin D responsive ele-
ments (VDRE) in the promoter region of vitamin D responsive genes, influencing 
gene transcription [21, 25]. These VDREs are upstream of many genes and thereby 
exert an effect on different functions of the body. The most well-known activity 
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of vitamin D in the body is its role in calcium homeostasis. By stimulating calcium 
absorption, vitamin D enhances bone density. However, vitamin D also plays a role 
in many other biological processes, including the control of cancer cell prolifera-
tion, skin function, cardiovascular disease and regulation of the immune system 
[20]. It has vasculo-protective roles, especially in blood vessels that are sensitive to 
inflammation [26]. Moreover, vitamin D is important in neurocognitive develop-
ment through its stimulation of nerve growth factor production [27].
2.3 Vitamin D: modulating immune responses
Vitamin D has also been described to affect both innate and adaptive immu-
nity and is therefore considered to be immunomodulatory, including control of 
effector functions, increasing barrier function and stimulating regulatory T cells 
[28]. 1,25(OH)2D binds to a VDR which is located intracellularly. Consequently, 
the VDR/RXR complex translocates to the nucleus and binds to a VDRE, thereby 
altering gene transcription [29]. Studies show that the required 1,25(OH)2D levels 
are likely to be higher than the average serum vitamin D levels to facilitate immuno-
modulation. To maintain bone health, 1,25(OH)2D serum levels should be around 
20 ng/mL or higher [30]. In contrast, 1,25(OH)2D levels should approximately be 
40–80 ng/mL to reach sufficient amounts necessary for immunomodulation. These 
high 1,25(OH)2D levels can be achieved by the autocrine and paracrine functions of 
immune cells regarding vitamin D [31]. As stated before, vitamin D exerts its effects 
through VDRs. These receptors are expressed in all immune cells, although in 
ranging amounts [31]. By binding of 1,25(OH)2D to VDRs, vitamin D can activate 
or suppress gene transcription. Additionally, 1,25(OH)2D can exert rapid non-
genomic responses. In contrast to genomic responses which require hours to days to 
become apparent, these rapid responses take 1 to 45 minutes [32]. Unfortunately, 
the exact mechanism of how this works has yet to be discovered.
Interestingly, immune cells can also affect 1,25(OH)2D levels. Most immune 
cells, including macrophages and dendritic cells, express CYP27B1 and CYP24A1, 
the enzymes needed for active vitamin D synthesis and degradation respectively. 
This allows immune cells to directly control 1,25(OH)2D levels in their direct local 
microenvironment, exerting autocrine and paracrine effects [33, 34]. This contrasts 
with systemic 1,25(OH)2D levels, which are regulated by CYP27B1, PTH and FGF23. 
Previous studies show that the negative feedback loop present in renal CYP24A1 and 
1,25(OH)2D does not apply to immune cell hydroxylases. Due to this, CYP24A1 is not 
activated by high levels of 1,25(OH)2D, resulting in increased vitamin D levels [35].
3. Peripheral immune dysregulation in ASD
ASD is characterized not only by behavioral deficits, but also by comorbidities, 
including gastrointestinal problems. In addition, there is an involvement of the 
immune system based on the increased inflammation, autoimmunity and oxida-
tive stress in ASD patients compared to healthy individuals [36]. Additionally, the 
prevalence of allergies and infections among ASD patients is higher compared to 
healthy individuals [37, 38]. A recent study states that approximately 60% of all 
ASD patients suffers from immune dysregulation [39, 40].
3.1 Antigen presenting cells
Studies indicate that innate immune activation with activated antigen presenting 
cells and associated cytokine production is observed in ASD patients [41]. Increased 
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numbers of monocytes with increased amounts of cytokines, with a shift towards 
pro-inflammatory cytokines are found in ASD patients compared to healthy 
individuals. IL-1β is one of these cytokines and is associated with more severe ASD 
symptoms. Upon TLR signaling, monocytes in ASD patients show increased activa-
tion and pro-inflammatory cytokine production [42, 43]. Macrophage or microglial 
activity associated with increased production of macrophage migration inhibitory 
factor (MIF) neuroinflammation in the brain is also altered in ASD patients [44]. 
MIF is a mediator of innate immunity by enhancing pro-inflammatory cytokine 
release and higher MIF levels result in less suppression of macrophage activity. 
Moreover, MIF levels are positively correlated with increased macrophage activity 
and thus ASD severity [45, 46]. Individuals with ASD show an increased number of 
dendritic cells, which is associated with more severe ASD symptoms [47]. These dif-
ferent findings thus illustrate increased innate immune activation in ASD patients.
Monocyte and macrophage activity are increased in ASD patients, both due 
to increased cell numbers and increased pro-inflammatory cytokine production. 
Contradictory, vitamin D suppresses pro-inflammatory cytokine release by M1 mac-
rophages, while antimicrobial activities and differentiation into M2 macrophages are 
stimulated. Like a balance between Th1 and Th2 cells, a balance between M1 and M2 
macrophages is required for immune homeostasis. An increase in both types of mac-
rophages could thus be beneficial, if a balance is maintained [48, 49]. Altogether, 
vitamin D balances macrophage function and is thereby likely to positively affect 
macrophage function in ASD patients. The number of dendritic cells is also increased 
in individuals with ASD, resulting in increased T cell activation and, indirectly, 
development of more severe symptoms [47]. In contrast, vitamin D can induce a 
tolerogenic state in dendritic cells. The expression of surface molecules required for 
antigen presentation and T cell activation is inhibited and a shift from pro-inflam-
matory to anti-inflammatory cytokine secretion arises. Via these pathways, vitamin 
D could affect dendritic cells in ASD patients in such a way that it facilitates immu-
nosuppression. Besides altered cytokine profiles that illustrate changes in CD4+ 
T cell differentiation, this shift in subsets is also shown by absolute cell numbers. 
Increased Th1 and Th17 populations are observed in ASD patients, combined with a 
decreased Treg population. Moreover, Tregs exhibit a reduced expression of Foxp3, 
CD25 and CTLA-4, which are all required for regulation of immune responses. 
Opposingly, vitamin D positively influences Th2 and Treg populations and hereby 
shifts immune responses to a more anti-inflammatory state [50, 51].
3.2 Pro-inflammatory cytokines
Altered cytokine expression has been observed in ASD patients with increased 
levels of pro-inflammatory cytokines IFN-y, IL-6, TNF-alpha, IL-8, IL-12, IL-17, 
IL-1ß, GM-CSF and MCP-1. IL-2 and IL-23. A meta-analysis described the strongest 
elevations were seen for IFN-y and thus Th1 cells stimulating inflammation and 
inhibiting Th2 proliferation in ASD patients compared to healthy individuals [52]. 
Besides, IL-6 is increased which as an important B cell activator enhances antibody 
production. In addition, IL-6 induces innate immune responses via the production 
of acute phase proteins [53]. Besides, IL-6 is important in signaling pathways in 
the central nervous system (CNS) by impairing synaptic plasticity and mediating 
behavioral deficits seen in ASD patients [54, 55]. IL-1ß has been shown to play a role 
in depression and anxiety through the hypothalamus-pituitary–adrenal (HPA) axis. 
Moreover, the role of IL-1ß has been suggested in training of the immune system. 
Upon excessive IL-1ß production, the immune system is characterized by less toler-
ance induction and increased prevalence of chronic inflammation [56]. However, a 
study reported no change in IL-1ß levels in ASD patients [57].
Vitamin D
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A study described significantly increased TNF-alpha, IL-6 and IL-17 levels and a 
decrease in IL-2 by peripheral blood samples of thirty ASD individuals compared to 
healthy controls [58]. Another study did not find significant alterations in IL-2 levels 
of ASD patients compared to healthy individuals [59]. TNF-alpha and IL-12 expres-
sion are consistently proven to be elevated in ASD patients [57, 60]. IL-17 expression 
is shown either to be increased [61–63] or similar in ASD patients compared to 
healthy individuals [64, 65]. Besides IL-17, IL-21 and IL-22 are two other important 
Th17 cytokines. These are both shown to be increasingly expressed in ASD patients 
[66]. Contradicting findings exist on the expression of IL-23, a cytokine impor-
tant in Th17 differentiation [64, 65, 67]. GM-CSF is shown to be elevated in ASD 
patients. This cytokine is important in the activation of Th17 cells and hereby plays a 
role in autoimmunity [68]. Contradictory, GM-CSF is also suggested to have ben-
eficial effects on ASD symptoms. For example, GM-CSF can cross the blood brain 
barrier and can act as neuronal growth factor [68]. GM-CSF was associated with 
improved development and behavior in ASD patients. Several chemokines, includ-
ing IL-8 and MCP-1, are also elevated in ASD patients. These chemokines have the 
capacity to attract T cells to tissue inflammation sites [69].
3.3 Anti-inflammatory cytokines
Several studies observe alterations in anti-inflammatory cytokines in ASD 
patients, like reductions in TGF-ß expression [70, 71]. TGF-ß being involved in 
immune regulation and is associated with severity of ASD symptoms; the lower the 
TGF-ß status, the more severe ASD symptoms are [72]. The levels of IL-10 in ASD 
patients remain debatable. Some studies observed increased IL-10 levels [69], while 
others found similar IL-10 levels [73] or even lower IL-10 levels [71, 74] in ASD 
patients compared to healthy individuals. IL-10 modulates inflammatory response 
and thus the observed increased inflammation in ASD patients could be expected 
to be increased. Lack of this compensatory activity of IL-10 suggests immune 
dysregulation. Lastly, IL-35 is also connected to regulatory T cells and was found 
to be reduced in ASD patients [75]. Meta-analysis findings suggest that the changes 
in IL-4, IL-5 and IL-13 levels in ASD patients are insignificant [70]. On the other 
hand, multiple studies observe increased concentrations of IL-4, IL-5 and IL-13 in 
ASD patients [76]. In general, a decreased level of anti-inflammatory cytokines is 
found in ASD patients. This can result in chronic inflammation in ASD patients [6].
In summary, pro-inflammatory cytokines and chemokines are all increasingly 
expressed in ASD patients while anti-inflammatory cytokines are downregulated. 
Nevertheless, other studies showed an increased expression of anti-inflammatory 
cytokines combined with a decreased expression of pro-inflammatory cytokines 
upon vitamin D treatment. Upon exposure to vitamin D, immune cells secrete 
increased amounts of the anti-inflammatory cytokines IL-10 and TGF-ß. At the 
same time vitamin D suppresses the production of pro-inflammatory cytokines and 
chemokines. This cytokine expression profile indicates that vitamin D might have 
protective effects against ASD development.
3.4 CD4+ T cell populations
In general, an increase in inflammatory Th1 and Th17 cells can be observed in 
individuals with ASD and were directly correlated with severity of symptoms  
[71, 77]. In contrast, increased Th2 responses are associated with improved behavior 
in children with ASD [72]. This suggests also beneficial effects of a Th2-skewed 
immune system in ASD patients. While mostly an increased Th1/Th2 ratio is 
observed in ASD patients compared to healthy individuals [78], others describe 
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increased Th2 relative to Th1 [72]. This contrast illustrates immune dysregulation in 
ASD patients [70]. In addition, a decreased Foxp3 expression positive Treg popula-
tion is observed [] as well as decreased CTLA-4 expression [72]. Also, CD25 expres-
sion in activated CD4+ and CD8+ T cells is decreased [66, 71], while others showed a 
decreased ratio [79].
The observed dysregulation of the immune system in individuals with ASD is 
important not only for developing symptoms, but also affects the severity of the 
symptoms. In general, it can be concluded that ASD patients have increased Th1- 
and Th17-mediated immune responses and decreased Th2 and Tregs cytokines. 
Due to the increased immune activation, chronic inflammation can occur and 
worsen ASD symptoms. Children with genetic heritability have a higher chance of 
developing ASD, and the role of a disbalanced immune system in ASD develop-
ment should be acknowledged.
3.5 Inflammation in ASD
In addition to peripheral immune dysregulation in ASD, other immunologi-
cal dysfunctions in ASD are also of importance. The role of neuroinflammation, 
autoimmunity and oxidative stress have been investigated more widely in ASD 
patients and the importance of these processes should be noted. The difference 
between systemic inflammation and neuroinflammation is reflected by the fact 
that some cytokines are differentially expressed in the brain versus systemically. 
Increased TGF-ß levels are measured in the cerebellum of ASD patients, in con-
trast to decreased levels in the cerebrospinal fluid or the periphery [80]. Upon 
cell death, cells often secrete TGF-ß to reduce local inflammation. Neurons that 
showed degeneration were high in TGF-ß, suggesting the increased TGF-ß levels 
found in the brain of ASD patients are targeted at controlling neuroinflamma-
tion. Increased microglial activation, combined with increased pro-inflammatory 
cytokines and i-NOS activation results in neuroinflammation [41]. This is observed 
in a large fraction of all ASD cases and could lead to impaired connectivity in the 
CNS, resulting in the pathophysiology observed in ASD patients. Moreover, oxida-
tive stress is increased in ASD patients, which is among others shown by increased 
i-NOS activation and the presence of reactive oxygen species. Oxidative stress can 
affect both immune cells and neurons, thereby causing neuroinflammation and 
neuron degeneration [36]. Vitamin D has been shown to increase glutamine, an 
antioxidant capable of counteracting the negative activities of free oxygen radicals, 
and to decrease nitric oxide. Via these ways, vitamin D could reduce oxidative stress 
in ASD patients [13].
Lastly, improving ASD symptoms is touched upon most in this review by 
discussing immune dysregulation in ASD, prevention of ASD is another topic 
that requires attention. While vitamin D is presumed to play a role in immune 
dysregulation, and thereby systemic inflammation in ASD patients, this is thought 
to be limited to the progression of ASD symptoms. ASD is a neurodevelopmental 
disorder, indicating the importance of the CNS in the etiology and pathophysiology 
of ASD. Considering the onset of ASD, neuroinflammation, rather than systemic 
inflammation, should be focused on. Vitamin D is proven to play an important role 
in neuronal development, which is also illustrated by the abundance of VDRs in 
the CNS [81]. Maternal vitamin D deficiency and risk of ASD have been commonly 
shown to be associated. When maternal vitamin D deficiency occurs, insufficient 
vitamin D impairs neurodevelopment in the infant [82] This illustrates the impor-
tance of adequate vitamin D levels during gestation. A recent study tested the effi-
cacy of vitamin D supplementation in pregnant mothers of children with autism on 
reducing the risk of autism in the newborn sibling [83]. After maternal vitamin D 
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supplementation and supplementation during the first three years of the newborn’s 
lives, the risk of autism was shown to be reduced from 20% to 5%. This illustrates 
the importance of adequate maternal vitamin D status and the influence on ASD 
risk. Vitamin D supplementation is likely to be effective at reducing inflammation 
in ASD patients and improve symptoms of ASD. However, to prevent ASD it is more 
relevant to look at maternal vitamin D supplementation and the role of vitamin D 
in neurodevelopment. Therefore, further research should be performed to examine 
the possible mechanisms of vitamin D during gestation and the association with 
ASD development in the infant.
4. Vitamin D and ASD: clinical results
The possibility of an association between vitamin D and ASD was found when 
studies concluded that ASD prevalence is increased in high-latitude countries 
and with more cloud coverage, resulting in reduced UV-B intensity. Many studies 
observe the connection between low sun exposure and risk of ASD [84]. UV-B 
exposure is required for the conversion of 7-dehydrocholesterol into previtamin D 
underscoring the link between UV exposure, vitamin D generation and ASD devel-
opment [85]. However, it was shown that vitamin D insufficiency in ASD patients is 
independent of sun exposure, ruling out the environmental factor causing vitamin 
D deficiency later in life. Moreover, ASD prevalence is suggested to be higher in 
dark skin-colored people compared to light skin-colored people [86]. It is suggested 
that increased skin pigmentation lowers the production of previtamin D, due to 
UV-B radiation that is absorbed by melanin and thereby less available for vitamin 
D synthesis [11]. For example, a study showed only 4.1% of the dark skin-colored 
pregnant women had sufficient vitamin D levels, compared to 37.3% in light skin-
colored pregnant women [87]. However, other studies state skin pigmentation does 
not influence vitamin D synthesis and that a different lifestyle, i.e. less exposure to 
sunlight, could explain lower vitamin D levels in dark skin-colored people [88, 89]. 
Thus, common vitamin D deficiency in dark skin-colored people might explain the 
higher ASD prevalence among this group, however results are contradictory regard-
ing the cause of lower vitamin D status.
4.1 Maternal vitamin D deficiency
ASD prevalence is increased in children of whom the mother was vitamin D 
deficient during gestation [87] and thus it is suggested that maternal vitamin D 
deficiency increases the risk of ASD in the infant [84, 90].
The possible role of maternal vitamin D deficiency is also illustrated by the 
influence of season of birth on ASD risk. Maternal vitamin D levels are often lowest 
in winter and spring months [91], which could be explained by differences in sun 
exposure and UV-B intensity [85, 91]. However, studies observe conflicting results 
regarding seasons most positively associated with ASD risk, questioning whether 
birth season is indeed a cofactor influencing the risk of ASD. Multiple studies 
observe highest ASD prevalence in children born in March [92]. These children have 
a higher risk of maternal vitamin D deficiency in the second half of gestation, since 
maternal 25(OH)D levels are lowest in winter and spring months. On the other 
hand, studies observing highest ASD prevalence among children born in May, July 
or August also exist [93–95]. Autumn months coincided with highest ASD preva-
lence, while birth in spring months reduced the risk of ASD [96]. Studies show that 
the first six months of gestation are most important for neurocognitive develop-
ment in the infant, a process which is influenced by vitamin D [97, 98]. Therefore, 
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it is suggested that maternal vitamin D deficiency increases the risk of ASD most 
when occurring in the first six months of gestation. As vitamin D levels are lowest 
in winter and spring, this would result in highest ASD prevalence among children 
who are born in summer. However, contradicting results on the association between 
birth season and ASD risk hinder a definite conclusion.
4.2 Vitamin D deficiency in ASD children
Studies show that children with ASD have lower vitamin D levels than healthy 
children. Since 2011, vitamin D insufficiency is classified as a 25(OH)D level 
between 20–30 ng/mL, whereas levels below 20 ng/mL are considered vitamin 
D deficient [3]. Individuals with ASD on average show 25(OH)D levels below 
30 ng/mL [99–101]. In a recent study, 48% of the ASD cases was vitamin D 
insufficient and 40% vitamin D deficient, whereas none of the healthy children 
were deficient and only 20% was insufficient [101]. This study used different 
cut-off values, resulting in the fact that when using the standard cut-off of 20 ng/
mL for vitamin D deficiency, the percentage of deficient children would even 
be higher than 40%. An average vitamin D level of 28.5 ng/mL was measured in 
ASD children, compared to 40.1 ng/mL in healthy children [102]. A significant 
negative correlation between vitamin D levels and severity of ASD symptoms 
was found, indicating low vitamin D levels can increase the severity of ASD 
[100]. When combining this finding with the previously mentioned association 
between season and vitamin D levels, this suggests the effect of season on ASD 
symptoms. Several case studies indeed observe that children with ASD experi-
ence less symptoms during summer compared to other seasons, which supports 
the plausible association between vitamin D and ASD [103].
In addition to the above-mentioned environmental factors that could cause 
vitamin D deficiency in ASD patients and are associated with progression of the 
disorder, genetics also play a role. In a study that compared vitamin D levels in 
ASD children and their healthy siblings, lower 25(OH)D levels were found in 
ASD children, suggesting genetics are upstream of vitamin D deficiency in ASD 
patients, rather than environmental factors [104]. Moreover, most studies on 
neonatal vitamin D levels and the association with ASD risk have found a negative 
correlation, illustrating that vitamin D deficiency presumably develops during 
gestation and is dependent on either or both genetics and maternal environmental 
factors [105, 106].
Furthermore, genetic polymorphisms are shown to be associated with impaired 
vitamin D metabolism and binding to VDR and can therefore predispose ASD. VDR 
gene polymorphisms were studied of which two were significantly associated with 
ASD [86]. Measured 25(OH)D serum levels did not significantly correlate with gene 
polymorphisms, suggesting vitamin D deficiency itself is not the cause of increased 
ASD risk, but rather genetic mutations. However, not all ASD patients suffer from 
these gene mutations and thus gene polymorphisms cannot explain all ASD cases 
[107]. To conclude, it is uncertain whether genetic or environmental factors alone 
predispose vitamin D deficiency in ASD patients. Nonetheless, clinical trials agree 
that reduced vitamin D levels are observed in ASD patients.
4.3 Vitamin D treatment in ASD patients
Due to the suggested association between vitamin D levels and ASD symptom 
severity, it is being investigated whether vitamin D supplementation could work 
as treatment to reduce ASD symptoms. The effect of vitamin D, n-3 fatty acids 
and the combination of the two were tested on ASD symptoms [108]. In the study, 
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children with ASD received a daily dose of 2000 IU vitamin D3 for twelve months. 
This study did not find a positive effect of only vitamin D supplementation on 
reducing ASD symptoms. However, treatment with n-3 fatty acids only or the 
combined treatment with vitamin D and n-3 fatty acids did improve social aware-
ness scores in children with ASD. In contrast, a positive effect of vitamin D treat-
ment was observed on ASD symptoms [109]. Autism Behavior Checklist (ABC) and 
Childhood Autism Rating Scale (CARS) scores were used, two methods commonly 
used for scoring ASD symptoms. Children with ASD received one monthly dose of 
150,000 IU vitamin D intramuscularly and daily doses of 400 IU vitamin D orally. 
After three months, both total ABC and total CARS scored were decreased signifi-
cantly. These reductions were prominent in ASD children under the age of three 
compared to ASD children above the age of three, suggesting vitamin D treatment 
possibly is more effective at a younger age. Similarly, vitamin D treatment can be 
effective at reducing ASD symptoms. Upon receiving daily doses of 300 IU vitamin 
D3 per kg bodyweight orally, 67 out of 83 children with ASD experienced improved 
symptoms [110]. The positive effect of vitamin D was most prominent in the group 
with 25(OH)D levels above 40 ng/mL at the end of the study, suggesting higher 
vitamin D levels correlate with increased improvement of behavior. Although 
research is limited, recent studies on the effect of vitamin D treatment in ASD 
children show promising results.
A review supported the need of a high vitamin D dose for its efficacy [31]. 
Whereas the recommended daily intake of vitamin D is 30 ng/mL, a minimum dose 
of 40–80 ng/mL is suggested for vitamin D to exert its immunomodulatory effects 
in general. In ASD, most improved ASD symptoms upon vitamin D administration 
above 40 ng/mL. Worldwide it is estimated that 30% of all children and adults are 
vitamin D deficient, and around 60% has insufficient vitamin D levels [110]. This 
high percentage of insufficiency cases illustrates the need for vitamin D supplemen-
tation and/or increased sun exposure when the effect of vitamin D on the immune 
system is wished upon. Presumably, this would not cause adverse effects as studies 
on the toxicity of vitamin D have found little disease outcomes, except possibly 
hypercalcemia [111]. However, findings on hypercalcemia are inconsistent and it is 
thus not known whether hypercalcemia will indeed occur in the case of vitamin D 
levels above 40–80 ng/mL and most likely at a dose of 150 ng/mL [3, 91].
All in all, many clinical trials have been performed on the association between 
vitamin D and ASD. Low vitamin D levels are observed more often in ASD children 
compared to healthy children. Moreover, research indicates the role of maternal vita-
min D deficiency in ASD is plausible and recent studies have illustrated the effective-
ness of vitamin D treatment on improving ASD symptoms. Thus, clinical trials show 
promising results on the association between vitamin D and ASD and the effective-
ness of vitamin D treatment in ASD patients. Lastly, rather than in ASD children 
there is still little research performed on immune functioning and vitamin D levels in 
adults with ASD as lower 25(OH)D levels were observed in adults with autistic dis-
order compared to healthy individuals [112]. The lack of research in this target group 
complicates extrapolation of the discussed results to adults. It is therefore uncertain 
whether vitamin D supplementation could improve ASD symptoms in adults.
5. Association vitamin D and ASD
The association between vitamin D and ASD is proven through clinical research. 
Clinical trials show promising results on vitamin D supplementation and the 
improvement of ASD symptoms. Characteristics of ASD, including behavioral 
deficits and impaired communicative functioning, impair the lifestyle of both 
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patients and their close relatives – improvement of symptoms therefore would be 
highly beneficial [113]. Insights into the mechanisms would support a better under-
standing of the etiology of the disorder. Consequently, this can enhance the finding 
of better preventive measures and treatments. Besides the lack of research into the 
mechanisms behind the effect of vitamin D on ASD, further research is also required 
to better understand immunomodulatory properties of vitamin D in general, as well 
as immune dysfunction in individuals with ASD [31]. Similarly, there is a lack of 
research on several important cytokines in ASD patients, like IL-21, IL-22 and IL-35. 
Additionally, IL-10 expression in ASD patients remains debatable. Different studies 
have found either reduced, similar or increased IL-10 levels compared to healthy 
individuals. This suggests the high interpersonal variability between ASD patients 
and the heterogeneous etiology of the disorder, emphasizing the need for further 
research to determine possible subgroups on which tailored treatment design could 
be based [114]. In addition, the role of IL-2 in regulating immune responses in ASD 
remains elusive. IL-2 is a Th1 cytokine, important for T cell proliferation of effector 
T cells but also for regulatory T cells. Vitamin D is shown to reduce IL-2 levels. This 
implies a reduction in Th1 cytokines, but as IL-2 is required for TGF-ß-mediated 
induction of CTLA-4 and Foxp3 expression on Tregs this suggests that increased 
IL-2 expression would enhance immunosuppression [115–117].
Although research on the association between vitamin D and ASD is receiving 
increased attention, no causality has been proven. As discussed, it is unknown 
whether vitamin D deficiency is caused by genetic or environmental factors. The 
possibility of reduced endogenous vitamin D production in ASD patients raises 
the question whether vitamin D insufficiency is a cause or consequence of ASD. 
To date, it is uncertain whether vitamin D deficiency predisposes ASD onset or is 
developed because of ASD. Effectiveness of vitamin D supplementation is irre-
spective of the outcome of causality, as clinical trials have shown promising results 
on the positive effect of vitamin D on ASD symptoms. However, increasing sun 
exposure could be less effective in the case of impaired endogenous vitamin D pro-
duction in ASD patients. Research on the mechanisms behind the role of vitamin 
D in ASD could support a better understanding of a possible causal relationship.
6. Conclusion
Vitamin D can have immunosuppressive effects on the immune system that 
could be of interest in ASD. By shifting immune responses away from Th1- and 
Th17-mediated towards Th2- and Treg-mediated, vitamin D promotes a tolerogenic 
state in the immune system. This could rebalance immune dysregulation in ASD, 
consequently reducing systemic inflammation among others. Clinical trials on the 
effect of vitamin D supplementation on improving ASD symptoms and reducing 
ASD risk are promising, highlighting the relevance of investigating vitamin D 
when studying ASD. This relevance is best illustrated by the finding that increased 
immune activity is positively correlated with severity of ASD symptoms, a process 
which could be counteracted by vitamin D. However, studies on the direct mecha-
nisms of vitamin D on the immune system in ASD patients are absent. Therefore, 
further research is necessary to draw conclusions about a possible causal relation-
ship. Moreover, further research into the mechanisms behind maternal vitamin 
deficiency and neuroinflammation are advised to investigate possible preventive 
actions of vitamin D in relation to ASD. Since vitamin D toxicity is rare, it is advised 
to increase vitamin D levels in pregnant women and ASD patients. However, insuf-
ficient research exists to state the effectiveness of vitamin D in regulating immune 
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